CKD |
Chronic kidney disease |
GFR |
Glomerular filtration rate |
NSAIDs |
Nonsteroidal anti-inflammatory drugs |
RAS |
Renin–angiotensin system |
AVP |
Arginine vasopressin |
ESRD |
End-stage renal disease |
KRT |
Kidney replacement therapy |
PA |
Physical activity |
BP |
Blood pressure |
T2DM |
Type 2 diabetes mellitus |
IR |
Insulin resistance |
e-GFR |
Estimated glomerular filtration rate |
CVD |
Cardiovascular disease |
CNS |
Central nervous system |
KD |
Ketogenic diets |
PKD |
Polycystic kidney disease if Intermittent fasting |
PBD |
Plant-based diets |
MRAs |
Mineralocorticoid receptor antagonist |
NT-proBNP |
N-terminal pro B-type natriuretic peptide |
FIDELIO-DKD |
Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease |
FIGARO-DKD |
Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease |
MR |
Mineralocorticoid receptor |
UACR |
Urine albumin-to-creatinine ratio |
ASCVD |
Atherosclerotic cardiovascular disease |
CV |
Cardiovascular |
FDA |
Food and Drug Administration |
IL-1β |
Interleukin 1β |
NLRP3 |
(NOD)-like receptor protein 3 |
FMF |
Familial Mediterranean fever |
sJIA |
Systemic juvenile idiopathic arthritis |
PDE |
Phosphodiesterase |
cAMP |
Cyclic adenosine monophosphate |
PKA |
Protein kinase A |
hs-CRP |
High-sensitivity C-reactive protein |
TNF-α |
Tumor necrosis factor α
|
PTF |
Pentoxifylline |
KDIGO |
Kidney Disease: Improving Global Outcomes |
PD |
Peritoneal dialysis |
HD |
Hemodialysis |
HDF |
Hemodiafiltration |
AFB |
Acetate-free biofiltration |
HF |
Hemofiltration |
HF |
Heart failure |
HIV |
Human immunodeficiency virus |
IDH |
Intradialytic hypotension |
SCD |
Sudden cardiac death |
OKT |
Open kidney transplantation |
RAKT |
Robot-assisted kidney transplantation |
TCMR |
T-cell mediated rejection |
ABMR |
Antibody-mediated rejection |
CKTR |
Chronic kidney transplant rejection |
IVIG |
Intravenous immunoglobulins |
PREDIAN |
Pentoxifylline for Renoprotection in Diabetic Nephropathy |
LEADER |
Liraglutide Effect and Action in Diabetes |
ARNI |
Angiotensin receptor-neprilysin inhibitor |
LVEF |
Left ventricle ejection fraction |
ACEI |
Angiotensin-converting enzyme inhibitor |
ARB |
Angiotensin II receptor blocker |
NICE |
National Institute for Health and Care Excellence |